Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIBBLE: FMD and Rapamycin in APOE4 Carriers
NCT06682767Phase 2Not yet recruiting
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Nov 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus in Alzheimer's disease (AD), sponsored by Cedars-Sinai Medical Center. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
sirolimus
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06682767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06682767.